St Johns wort increases expression of P-glycoprotein: implications for drug interactions.
暂无分享,去创建一个
D. Back | M. Barry | J. Feely | F. Mulcahy | M. Hennessy | J. Spiers | D. Kelleher | P. Kavanagh
[1] Oliver Burk,et al. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.
[2] P. Meier,et al. St John's Wort induces intestinal P‐glycoprotein/MDR1 and intestinal and hepatic CYP3A4 , 2000, Clinical pharmacology and therapeutics.
[3] J. Mellors,et al. 3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine , 2000, Annals of Internal Medicine.
[4] R. Obach,et al. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. , 2000, The Journal of pharmacology and experimental therapeutics.
[5] L. Moore,et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Burstein,et al. St John's Wort: Effect on CYP3A4 activity , 2000 .
[7] E. Schrader. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mildmoderate depression , 2000, International clinical psychopharmacology.
[8] A. Schinkel,et al. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors , 2000, AIDS.
[9] D. Dormont,et al. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. , 2000, AIDS.
[10] F. Ruschitzka,et al. Acute heart transplant rejection due to Saint John's wort , 2000, The Lancet.
[11] J. Falloon,et al. Indinavir concentrations and St John's wort , 2000, The Lancet.
[12] B. Gaster,et al. St John's wort for depression: a systematic review. , 2000, Archives of internal medicine.
[13] S. Risch,et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.
[14] E. Ernst,et al. Second thoughts about safety of St John's wort , 1999, The Lancet.
[15] B. Goodwin,et al. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. , 1999, Molecular pharmacology.
[16] R. Farinotti,et al. Kinetics of Antiviral Activity and Intracellular Pharmacokinetics of Human Immunodeficiency Virus Type 1 Protease Inhibitors in Tissue Culture , 1999, Antimicrobial Agents and Chemotherapy.
[17] D. Back,et al. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. , 1999, British journal of clinical pharmacology.
[18] J. Kovarik,et al. Longitudinal assessment of a P‐glycoprotein–mediated drug interaction of valspodar on digoxin , 1999, Clinical pharmacology and therapeutics.
[19] I. Roots,et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.
[20] J. Streltzer,et al. St. John's wort for depression: a meta-analysis of well-defined clinical trials. , 1999, The Journal of nervous and mental disease.
[21] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[22] G. Ehninger,et al. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. , 1999, Leukemia research.
[23] J. Schapiro,et al. Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.
[24] C. Beglinger,et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. , 1999, Biochemical pharmacology.
[25] David Back,et al. Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection , 1999, Clinical pharmacokinetics.
[26] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[27] M. Franklin,et al. Determination of hypericin in plasma by high-performance liquid chromatography. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[28] J. Pepping. St. John's wort: Hypericum perforatum. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[29] K. Sugimoto,et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. , 1999, Blood.
[30] B. Lacarelle,et al. Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. , 1998, Biochemical and biophysical research communications.
[31] R. Kessler,et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. , 1998, JAMA.
[32] W. Sabbagh,et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.
[33] R Ohlsson,et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Hsu,et al. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. , 1998, Clinical pharmacokinetics.
[35] J. Lehmann,et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.
[36] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[37] I. Pastan,et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.
[38] J. Lehmann,et al. An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.
[39] J. Beijnen,et al. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.
[40] T. Grogan,et al. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins , 1997, Leukemia.
[41] A. Breckenridge,et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients , 1997, AIDS.
[42] C. Mulrow,et al. St John's wort for depression—an overview and meta-analysis of randomised clinical trials , 1996, BMJ.
[43] F. Lanuzza,et al. High-performance liquid chromatographic determination of the biologically active principle hypericin in phytotherapeutic vegetable extracts and alcoholic beverages. , 1996, Journal of chromatography. A.
[44] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[45] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[46] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[47] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.